{"id":87855,"date":"2024-12-06T14:49:06","date_gmt":"2024-12-06T14:49:06","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/"},"modified":"2024-12-06T14:49:06","modified_gmt":"2024-12-06T14:49:06","slug":"aim-immunotech-participates-in-virtual-investor-kol-connect-segment","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/","title":{"rendered":"AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment"},"content":{"rendered":"
\n

Segment featuring Dr. Charles Lapp, ME\/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available <\/em>here<\/u><\/em><\/a><\/p>\n

OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc.<\/strong><\/a> (NYSE American: AIM)\u00a0<\/strong>(\u201cAIM\u201d or the \u201cCompany\u201d), today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp<\/a>, AIM\u2019s Consulting Medical Officer. Dr. Lapp is also the founder of the Hunter-Hopkins Center in Charlotte, N.C., and a Key Opinion Leader who has been treating Chronic Fatigue Syndrome and Fibromyalgia for over 25 years.<\/p>\n

As part of the segment, Dr. Lapp discussed results<\/a> from AIM\u2019s Phase 2 study evaluating the efficacy and safety of Ampligen\u00ae as a potential therapeutic for people with the Post-COVID condition of fatigue (\u201cAMP-518\u201d; NCT05592418<\/a>).<\/p>\n

The Virtual Investor KOL Connect Segment can be accessed here<\/a>.<\/p>\n

About AIM ImmunoTech Inc.<\/strong><\/p>\n

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company\u2019s lead product is a first-in-class investigational drug called Ampligen\u00ae<\/sup>\u00a0(rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.<\/p>\n

For more information, please visit\u00a0aimimmuno.com<\/a>\u00a0and connect with the Company on\u00a0X<\/a>,\u00a0LinkedIn<\/a>, and\u00a0Facebook<\/a>.<\/p>\n\n <\/div>\n","protected":false},"excerpt":{"rendered":"

Segment featuring Dr. Charles Lapp, ME\/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM)\u00a0(\u201cAIM\u201d or the \u201cCompany\u201d), today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp, AIM\u2019s Consulting Medical Officer. […]<\/p>\n","protected":false},"author":2,"featured_media":87856,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/8e85b83b-047f-4f99-9c51-1aa232ffe9bb","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-87855","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t